Abstract
Glycosylation is one of the major post-translational modifications, required for proper folding and functions of glycoproteins. N-glycosylation in ER is mediated by oligosaccharyltransferase (OST), an enzyme complex transferring preassembled oligosaccharide to asparagine residues of nascent polypeptide chain. Our study here indicates that regulator of calcineurin 1 (RCAN1) can enhance N-glycosylation in ER, therefore elevates the activities of β- and γ-secretase and markedly increases Aβ production. We found that RCAN1 stabilizes OST by interacting with OST component ribophorinI (RPN I). RCAN1 enhanced glycosylation of membrane proteins and glycosylation sequon GNSTVT, but has no effect on transferrin whose glycosylation was only affected by OST catalytic subunit STT3A, suggesting the effect of RCAN1 is associated with RPN I in facilitating substrate delivery. Our previous studies have shown that RCAN1 was increased in AD brains and RCAN1 overexpression induced neuronal apoptosis. Here our study showed that RCAN1 further contributes to AD pathogenesis by increasing N-glycosylation and Aβ production.
Keywords: Aβ, Alzheimer’s disease, β-secretase, γ-secretase, N-glycosylation, oligosaccharyltransferase, RCAN1.
Current Alzheimer Research
Title:RCAN1 Increases Aβ Generation by Promoting N-glycosylation via Oligosaccharyltransferase
Volume: 11 Issue: 4
Author(s): Tan Wang, Heng Liu, Yun Wang, Changqing Liu and Xiulian Sun
Affiliation:
Keywords: Aβ, Alzheimer’s disease, β-secretase, γ-secretase, N-glycosylation, oligosaccharyltransferase, RCAN1.
Abstract: Glycosylation is one of the major post-translational modifications, required for proper folding and functions of glycoproteins. N-glycosylation in ER is mediated by oligosaccharyltransferase (OST), an enzyme complex transferring preassembled oligosaccharide to asparagine residues of nascent polypeptide chain. Our study here indicates that regulator of calcineurin 1 (RCAN1) can enhance N-glycosylation in ER, therefore elevates the activities of β- and γ-secretase and markedly increases Aβ production. We found that RCAN1 stabilizes OST by interacting with OST component ribophorinI (RPN I). RCAN1 enhanced glycosylation of membrane proteins and glycosylation sequon GNSTVT, but has no effect on transferrin whose glycosylation was only affected by OST catalytic subunit STT3A, suggesting the effect of RCAN1 is associated with RPN I in facilitating substrate delivery. Our previous studies have shown that RCAN1 was increased in AD brains and RCAN1 overexpression induced neuronal apoptosis. Here our study showed that RCAN1 further contributes to AD pathogenesis by increasing N-glycosylation and Aβ production.
Export Options
About this article
Cite this article as:
Wang Tan, Liu Heng, Wang Yun, Liu Changqing and Sun Xiulian, RCAN1 Increases Aβ Generation by Promoting N-glycosylation via Oligosaccharyltransferase, Current Alzheimer Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567205011666140331225855
DOI https://dx.doi.org/10.2174/1567205011666140331225855 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association Between Immunologic and Virologic Functioning and Health-Related Quality of Life Among People Living with HIV, Tehran, Iran
Infectious Disorders - Drug Targets Trait vs. State Markers for Schizophrenia: Identification and Characterization Through Visual Processes
Current Psychiatry Reviews Mediterranean Diet and Risk of Dementia
Current Alzheimer Research Recent Progress in FKBP Ligand Development
Current Molecular Pharmacology Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
Current Neuropharmacology A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design Optimization of Extraction and Pre-Concentration of Rizatriptan in Biological Samples Using Solvent Bar and Chemometrics Design
Current Pharmaceutical Analysis Aminoalkylated Phenolic Chalcones: Investigation of Biological Effects on Acetylcholinesterase and Carbonic Anhydrase I and II as Potential Lead Enzyme Inhibitors
Letters in Drug Design & Discovery Whole Brain Atrophy and Sample Size Estimate via Iterative Principal Component Analysis for Twelve-month Alzheimer's Disease Trials
Neuroscience and Biomedical Engineering (Discontinued) Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Ibandronate in Benign Bone Disease
Reviews on Recent Clinical Trials Editorial: [Hot Topic: Keeping Track of an Expanding Subject - Recent Trends in Immunology and their Clinical Implications]
Current Pharmaceutical Design Sensing, Transport and Other Potential Biomedical Applications of Pseudopeptides
Current Medicinal Chemistry Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design Mean Diffusivity in the Dopaminergic System and Neural Differences Related to Dopaminergic System
Current Neuropharmacology Capillary Electrophoresis with Mass Spectrometry: Applications to Metabolomic Analysis
Current Metabolomics Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Current Pharmaceutical Design Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research